非小细胞肺癌中新型基因间区-ALK融合对阿来替尼耐药的病例报告数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases.docx
• DOI：10.3389/fonc.2022.916315.s001
• 发布日期：2022-07-22
• 文件数：1 个
• 文件总体积：19.55 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Case_report_Two_novel_intergenic_region-ALK_fusions_in_non-small-cell_lung_cancer_resistant_to_alectinib_A_report_of_two_cases_docx/20357892

命令行下载

curl -L -o "DataSheet_1_Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases.docx" "https://ndownloader.figshare.com/files/36388008"

文件清单

• DataSheet_1_Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases.docx（19.55 KB）

文件总体积 19.55 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundThe anaplastic lymphoma kinase (ALK) mutation, also known as the diamond mutation in non–small-cell lung cancer (NSCLC), has been treated with tremendous success since it was first reported in 2007. Alectinib, a second generation ALK-Tyrosine kinase inhibitor (TKI), has been reported to have significantly longer progression- free survival (PFS) than first generation ALK inhibitors in untreated ALK positive NSCLC. However, the clinical efficacy of ALK-TKIs on rare ALK fusions remains unclear. In recent years, with the popularity of next-generation sequencing (NGS) technology, an increasing number of novel ALK fusion partners have been reported, but the responses are heterogeneous among different ALK fusions. Considering the inconsistent reactions, the clinical efficacy of ALK-TKIs in rare ALK gene fusions remains to be evaluated in more cases.
MethodsTo seek for individualized therapy, the tumor tissues acquired during biopsy were sent for genomic testing by NGS based on a 139-gene panel and a 425-gene panel in a centralized clinical testing center (GENESEEQ Technology Inc, Nanjing, China). See Supplementary Material for more details about the methods for DNA-based NGS, RNA-based NGS.
ResultsWe present two cases of patients with lung adenocarcinoma harboring two novel Intergenic Region (IGR)-ALK rearrangements detected by DNA sequencing, which had limited clinical response to ALK-TKIs but showed sensitivity to chemotherapy combined with bevacizumab therapy in patient 2, with a PFS of over 1 year up till the last follow‐up assessment.
ConclusionsIn summary, our cases emphasize the need for comprehensive molecular analysis of different ALK fusion partners at the DNA level to formulate accurate treatment strategies and provide a certain therapeutic reference for these two types of novel IGR-ALK fusions.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2022.916315.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Case_report_Two_novel_intergenic_region-ALK_fusions_in_non-small-cell_lung_cancer_resistant_to_alectinib_A_report_of_two_cases_docx/20357892）。